TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05607420: Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

Sponsor: Cellectis S.A. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,727,880

Rescue Site Savings

+$1,138,830

Unlock Full NCT05607420 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05607420 Rescue Dossier →